TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06136884: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

Sponsor: A2A Pharmaceuticals Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 86 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,440,280

Rescue Site Savings

+$4,241,160

Unlock Full NCT06136884 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06136884 Rescue Dossier →